Pulse Interleukin-2 with Famotidine Induces CD56+ Lymphocytes in the Peripheral Blood of Patients with Metastatic Melanoma or Kidney Cancer-Reference-Cited by-同舟云学术

Pulse Interleukin-2 with Famotidine Induces CD56+ Lymphocytes in the Peripheral Blood of Patients with Metastatic Melanoma or Kidney Cancer

Published:2011-02 Issue:1 Volume:26 Page:65-67
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Quan Walter D.Y.¹,Gagnon Gregory A.²,Walker Paul R.³,Quan Francine M.⁴

Affiliation:

1. Department of Medical Oncology, Loma Linda University School of Medicine, Loma Linda, California.

2. Department of Pathology and Laboratory Medicine, East Carolina University Brody School of Medicine, Greenville, North Carolina.

3. Division of Hematology/Oncology, East Carolina University Brody School of Medicine, Greenville, North Carolina.

4. Cancer Center, Loma Linda University School of Medicine, Loma Linda, California.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2010.0879

Reference13 articles.

1. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

2. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

3. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. H2 antihistamines: May be useful for combination therapies in cancer?;Biochemical Pharmacology;2024-05

2. Histamine in cancer immunology and immunotherapy. Current status and new perspectives;Pharmacology Research & Perspectives;2021-10

3. Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer;Expert Opinion on Biological Therapy;2020-10-03

4. Clinically feasible approaches to potentiating cancer cell-based immunotherapies;Human Vaccines & Immunotherapeutics;2015-04-03

5. Activity of Outpatient Intravenous Interleukin-2 and Famotidine in Metastatic Clear Cell Kidney Cancer;Cancer Biotherapy and Radiopharmaceuticals;2014-03